DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201

ONC201 is the first selective antagonist of dopamine receptor D2 (DRD2) and D3 (DRD3) for clinical oncology that has exhibited preliminary clinical activity in high grade gliomas. We investigated DRD2 dysregulation in glioma and its role in ONC201 efficacy. Investigating CRISPR screens across a spec...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Vijay Prabhu, Varun, Madhukar, Neel, Gilvary, Coryandar, Kline, C Leah B, Tarapore, Rohinton, El-Deiry, Wafik, Doherty, Faye, VanEngelenburg, Alexander, Durrant, Jessica, Benes, Cyril, Oster, Wolfgang, Elemento, Olivier, Allen, Joshua
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216484/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.317
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items